Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has reported earnings for its second fiscal quarter (ending June 30) of $0.20 versus $0.01 for the same period a year ago — an increase of 1900%. This result exceeded the consensus estimate of $0.18 by $0.02. For the latest four quarters through June 30, E.P.S. were $0.18 compared to $-0.69 a year ago.
Recent Price Action
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock closed at $18.85 on 8/6/24 after a large increase of 2.4%. Moreover, this advance was accompanied by unusually high trading volume at 183% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 0.5% during the last week.
Current PriceTarget Research Rating
ACAD is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Acadia Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Acadia Pharmaceuticals has a very low Appreciation Score of 14 and a very low Power Rating of 2, leading to the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment